Physician profile
Donna Tran
NPI 1457614919
$2,808.06
in general payments reported to CMS, 2019-2025
24 companies · $631 in 2025
The $631 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $455 · 2020: $28.82 · 2021: $328 · 2022: $121 · 2023: $653 · 2024: $591 · 2025: $631.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,875.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,875.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $969.55 | 2019-2025 | Rinvoq, Skyrizi |
| Pfizer INC. | $411.59 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $281.78 | 2019-2025 | |
| Genzyme Corporation | $182.26 | 2021-2025 | |
| Lilly USA, LLC | $120.05 | 2025 | Ebglyss |
| Almirall LLC | $111.76 | 2019 | |
| Incyte Corporation | $109.85 | 2022-2023 | Opzelura |
| Sanofi-Aventis U.S. LLC | $90.61 | 2021 | |
| Sun Pharmaceutical Industries INC. | $82.27 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $60.67 | 2023-2024 | Jardiance |
| Regeneron Healthcare Solutions, INC. | $56.96 | 2021-2025 | Libtayo |
| Amgen INC. | $52.39 | 2023-2024 | Otezla |
| Leo Pharma INC. | $45.14 | 2019-2023 | Adbry |
| Galderma Laboratories, L.P. | $43.63 | 2019-2024 | |
| Ucb, INC. | $32.25 | 2019-2024 | Bimzelx |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Revance Therapeutics, INC. | $28.86 | 2024-2025 | Daxxify |
| Solta Medical, A Division of Bausch Health US, LLC | $24.43 | 2025 | |
| Biofrontera INC. | $16.61 | 2024 | Ameluz, Xepi, Bf-Rhodoled |
| Takeda Pharmaceuticals U.S.A., INC. | $15.95 | 2019 | |
| Dermira, INC. | $15.63 | 2019 | |
| Medimetriks Pharmaceuticals, INC. | $14.52 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $13.96 | 2019 | |
| Misonix INC | $13.69 | 2021 | |
| Vyne Pharmaceuticals INC. | $13.65 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donna Tran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.